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Aims Several intracellular mediators have been implicated as new therapeutic targets against myocardial ischaemia and reper-
fusion injury. However, clinically effective salvage pathways remain undiscovered. Here, we focused on the potential role
of the adaptor protein p66Shc as a regulator of myocardial injury in a mouse model of cardiac ischaemia and reperfusion.
Methods
and results
Adult male p66Shc deficient (p66Shc2/2) and C57Bl/6 wild-type (WT) mice were exposed to 30, 45, or 60 min of ischae-
mia and reperfusion (5, 15 min, or 24 h). Infarct size, systemic and intracardiac inflammation and oxidants, as well as cyto-
solic and mitochondrial apoptotic pathways were investigated. Following 30, but not 45 or 60 min of ischaemia, genetic
p66Shc deficiency was associated with larger infarcts. In WT mice, in vivo p66Shc knock down by siRNA with transient
protein deficiency confirmed these findings. P66Shc inhibition was not associated with any modification in post-infarction
inflammation, oxidative burst nor cardiac vessel density or structure. However, in p66Shc2/2 mice activation of the pro-
tective and anti-apoptotic Reperfusion Injury Salvage Kinases and Survivor Activating Factor Enhancement pathways were
blunted and mitochondrial swelling and cellular apoptosis via the caspase-3 pathway increased compared with WT.
Conclusions Genetic deletion of p66Shc increased susceptibility to myocardial injury in response to short-term ischaemia and reperfu-
sion in mice. Still, additional studies are needed for assessing the role of this pathway in acute coronary syndrome patients.
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Translational perspective
Genetic deletion of p66Shc, as shown in the present study, leads to increased myocardial infarction in response to short-term ischaemia and
reperfusion. Therefore, heart-specific activation of p66Shc protein may represent a promising novel strategy to prevent ischaemic and reper-
fusion myocardial injury. In particular, pharmacological modulation of apoptosis via myocardial salvage pathways involving p66Shc might be a
promising approach to limit short-term ischaemic injury, for instance in patients with acute coronary syndrome (ACS) from the time of
symptom onset to percutaneous coronary intervention. However, the present study also adds complexity to the use of this pathway as a
therapeutic target. Indeed, given the different effects of activation and silencing of p66Shc in different cells, tissues and organs, tissue selective
inhibition would be required. Indeed, while short-term activation might be protective in the context of an ACS, long-term inhibition may
prevent endothelial dysfunction, atherosclerosis, and diabetic vascular disease. Obviously, this complexity also raises safety concerns for
the potential use of p66Shc in acute myocardial infarction that need to be clarified by additional research.
Introduction
Myocardial injury during short-term ischaemia and reperfusion has
become clinically important with the use of primary percutaneous
coronary angioplasty as a first-line strategy in patients with acute cor-
onary syndrome (ACS). Indeed, time from symptom onset to reper-
fusion is a major determinant of outcome.1 Thus, activation of
protective pathways during this vulnerable period of ACS remains
a clinical need. Knowledge of the mechanisms of myocardial ischae-
mia and reperfusion has been deepened with the use of animal
models of human disease.2,3 Several molecular and cellular targets
involved in cardiac injury and repair have been identified that are acti-
vated to protect cardiomyocytes from ischaemic insults.4– 7 Indeed, a
large number of protein kinases are activated at different levels and
time points during ischaemia–reperfusion injury. Recently, three dis-
tinct cardioprotective pathways for those protein kinases have been
proposed.8 The first is activated during the initial and middle phase of
acute ischaemic preconditioning and includes activation of phosphoi-
nositide 3 kinase (PI3K)/Akt and in turn endothelial nitric oxide syn-
thase (eNOS) and nitric oxide, followed by guanylate cyclase and
protein kinase C activation leading to activation of the ATP-
dependent mitochondrial potassium channels and generation of re-
active oxygen species (ROS),9,10 finally activating mitogen-activated
protein kinase p38 and mitochondrial permeability pore (mPTP)
opening.11 The secondbecomesactiveduring theearly in reperfusion
and results in the activation of the Reperfusion Injury Salvage Kinases
(RISK) pathway, which comprises PI3K and extracellular signal-
regulated mitogen-activated protein kinase (ERK1/2), and leads to
the inhibition of mPTP opening. The third is recruited during ischae-
mic pre- and post-conditioning and includes the Survivor Activating
Factor Enhancement (SAFE) pathway, which comprises signal trans-
ducer and activator of transcription (Stat) and results in rearrange-
ments in the nucleus and mitochondria.12 The complex interplay
between these intracellular pathways remains largely unknown, but
might represent a promising target to reduce cardiac damage
during ischaemia and reperfusion.
In this context, cardiacROSreleased following ischaemia-reperfusion
are of interest as regulators of cardiac salvage pathways.13 To investigate
this, we focused on the adaptor protein p66Shc which regulates cellular
redox states, metabolism and life span and is a critical mediator of oxi-
dative signal transduction.14–17 p66Shc acts not only in the cytosol but
uponphosphorylationalsoasa specific redoxenzyme inmitochondria,
generating hydrogen peroxide.18 As such, the adaptor protein
p66Shc might regulate ischaemia–reperfusion damage.19,20 However,
whether such effects occur in vivo remains unknown.
Thus, we designed an in vivo study to investigate the role of this
protein in a mouse model of ischaemia and reperfusion taking advan-
tage of genetic deletion of p66Shc or transient in vivo knock down of
the adaptor protein. In this setting, we investigated infarct size as
well as activation of intracellular salvage or apoptotic pathways and
their regulation by p66Shc.
Materials and methods
Animals
P66Shc2/2 knockout mice were originally obtained from the Centro
Nationale di Oncologia, Milano, Italy.15 The p66Shc deficient mouse
colony was maintained in the own animal facility by crossbreeding homo-
zygous animals. All animal experiments were performed on 12- to
14-week-old p66Shc2/2 knockout and wild-type (WT) male mice. Both
animal cohorts were maintained on identical C57Bl/6 genetic back-
ground. Genotyping was performed by PCR on ear punch biopsies
using p66Shc-specific primers (data not shown).
All mice were maintained at 248C with 12 h light–dark cycle and free
access to food and water. They were kept on a standard western type
chow. All procedures were approved by local ethics committees (both
in Zurich and Geneva) and Swiss authorities and conformed to the
‘position of the American Heart Association on Research Animal Use’
and ARRIVE guidelines.
In situ hybridization
P66Shc In situ hybridization was performed using Leica BOND-MAXTM
(Leica Biosystems, Buffalo Grove, IL, USA). Briefly, isolated murine WT
and p66Shc2/2 hearts were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 24 h. Formalin-fixed paraffin-embedded tissue
sections (5 mm) were deparaffinized in xylene, rehydrated in ascending
alcohols, digested with Enzyme 2 (5 g/mL) for 15 min at ambient tem-
perature. Samples (heart sections) were then denatured on a hot plate
for 3 min at 908C, and incubated for 1 h at 538C in hybridization buffer
(Exiqon, Woburn, MA, USA) containing 250 nM of double digoxigenin-
labeled p66Shc LNA mRNA detection probe (Exiqon). After incubation,
the samples werewashed twice in BOND washing buffer at ambient tem-
perature for 5 min. The samples were incubated in blocking solution
(AB-Blocking kit, Cell Marque, Rocklin, CA, USA), supplemented with
1 : 500 mouse anti-digoxigenin secondary Ab (Sigma) in BOND diluent
buffer (Leica Biosystems) and detected with the BOND Polymer
Refine Detection kit (Leica Biosystems).
In vivo knockdown of p66Shc
In vivo knockdown of p66Shc was performed by injecting a predesigned
siRNA specifically targeting p66Shc (5′-UGA GUC UCU GUC AUC
GCU G dTdT-3′, Microsynth AG, Switzerland). A scrambled siRNA
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was used as a negative control (5′-UAC ACA CUC UCG UCU CU
dTdT-3′, Microsynth AG, Switzerland). Amount of p66Shc siRNA was
selected based on dose optimization studies (data not shown).
The siRNA mix at the final dose of 1.6 mg/kg was incubated with the
in vivo-jetPEI delivery reagent (Polyplus-Transfection, Inc., New York,
NY, USA) for 15 min at room temperature and intravenously injected
in a final volume of 160 mL, as previously reported.21 Successful knock-
down of p66Shc was assessed by western blot in heart lysates.
In vivo pharmacological inhibition of Stat3
Some WT and p66Shc2/2 knockout mice were pretreated with WP1066
(40 mg/kg, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or
vehicle (10% DMSO in PBS) by intraperitoneal injection 5 min before is-
chaemia onset. Then, at 24 h of reperfusion, mice were euthanized and
infarct size was histologically determined by triphenyltetrazolium chlor-
ide (TTC) staining.
Ischaemia and reperfusion in vivo
P66Shc2/2 and WT (including those injected with siRNA) male mice
(10–12 weeks of age) were initially anaesthetized with 4% isoflurane
and intubated. After starting mechanical ventilation (tidal volume of
150 mL, 120 breaths/min) by supplementation with 100% oxygen, anaes-
thesia wasmaintained with 2% isoflurane. During surgery anaesthesiawas
monitored by careful visual and tactile control of mouse consciousness
(i.e. breathing rate and volume, heart rate, sweating and tearing). A thora-
cotomy was performed in the left third intercostal space and the pericar-
dium was removed. Ligature of the left anterior coronary artery at the
inferior edge of the left atrium was performed using an 8-0 Prolene
suture. A small piece of polyethylene tube was used to secure the ligature
without damaging the artery.
After 30, 45, or 60 min of ischaemia, the occlusion of the left anterior
coronary artery occlusion was released and reperfusion occurred. Anal-
gesia was extended with s.c. injection of 0.05 mg/kg buprenorphine HCl
every 12 h till sacrifice. Reperfusion was confirmed by visible restoration
of colour to the ischaemic tissue. Then, chest was closed and the ventila-
tor removed to restore normal respiration. After 24 h of reperfusion,
animals were anaesthetized with 4% isoflurane and i.p. injection of
ketamine–xylazine (4 mg/0.2%) and sacrificed for infarct size determin-
ation and immunohistochemical analyses.
Area at risk and myocardial infarct size (I)
assessment
To assess area at risk (AAR) and infarct size (I ) in in vivo myocardial pro-
tocols,micewereanaesthetizedwithketamine–xylazineand sacrificed at
24 h of reperfusion, as described.22 Left anterior coronary artery was
re-occluded before the heart was taken out. Next, Evan’s blue dye (2%;
Sigma, St. Louis, MI, USA) was injected into the aortic cannula to delineate
the in vivo AAR. The heart was rapidly excised and rinsed in NaCl 0.9%.
Then, hearts were frozen and sectioned into 2-mm transverse sections
from the apex to the base (5–6 slices/heart). The sections were incu-
bated at 378C with 1% TTC (Sigma) in phosphate buffer (pH 7.4) for
15 min, fixed in 10% formaldehyde solution and photographed with a
digital camera (Nikon Coolpix) to distinguish continuously perfused
tissue (blue), stained ischaemic viable tissue (red), and unstained necrotic
tissue (white). The different zones were determined using MetaMorph
software (version 6.0, Universal Imaging Corporation). Area at risk and
left ventricular I were expressed as percentage of ventricle surface
(AAR/V) and AAR (I/AAR), respectively.
Detection of cardiac troponin I and
inflammatory mediators in mouse serum
Circulating cardiac troponin I (cTnI) levels were measured in serum after
24 hof reperfusion,using ahigh-sensitiveELISA kit (LifeDiagnostics, Inc.).
Serum levels of CXCL1 and CCL2 were measured by colorimetric
enzyme-linked immunosorbent assay (ELISA,R&D Systems, Minneapolis,
MN, USA), following manufacturer’s instructions. The limit of detection
was 0.156 ng/mL for cTnI, 15.6 pg/mL for CXCL1, 7.8 pg/mL for CCL2.
Mean intra- and interassay coefficients of variation were ,6% for all
mediators.
Immunostaining
Hearts from animals sacrificed both before and after 30 min of ischaemia
and 24 h of reperfusion were frozen in optimal cutting temperature and
serially cut from the occlusion locus to the apex in 7 mm sections. Immu-
nostainings for neutrophils (anti-mouse Ly-6G Ab, dilution 1 : 100; BD
PharmingenTM, San Jose, CA, USA), macrophages (anti-mouse CD68
Ab, dilution: 1 : 400; ABD Serotec, Dusseldorf, Germany), endothelial
(anti-mouse CD31 Ab, dilution 1 : 500, Santa Cruz Biotechnology) or
smooth muscle cells (anti-mouse smooth muscle actin Ab, dilution 1 :
20, Thermo Scientific, Inc., Waltham, MA, USA) were performed on
five midventricular cardiac or brain sections per animal, and quantifica-
tion performed with the MetaMorph software, as previously
described.22 –24
Oxidative stress determination in mouse
infarcted hearts
Measurement of O2
− in mouse hearts at 30 min of ischaemia and 24 h
of reperfusion was performed using the O2
−-sensitive dye dihydroethi-
dium (DHE, Molecular Probes, Life Technologies Corporation, Zug,
Switzerland) as previously described.22 Five frozen midventricular
cardiac sections per animal were used, and nuclei were stained with
4′,6-diamidino-2-phenylindole. In situ fluorescence was assessed using
fluorescence microscopyand quantification performed with MetaMorph
software.
The production of other ROS was assessed by two histological med-
iators: the highly toxic product of lipid membrane peroxidation
4-hydroxy-2-nonenal (mouse anti-4-HNE monoclonal antibody at
1 mg/mL, Oxis International, Inc., Foster City, CA, USA) and the
3,5-dibromotyrosine (mouse anti-Di bromo tyrosine monoclonal anti-
body at 10 mg/mL, AMS biotechnology, LTD, Abingdon, UK).22
To avoid any potential cross-reactivity with mouse heart antigens and
to increase the specificity of the primary antibodies, the VECTOR
M.O.M Immunodetection kit and the VECTOR VIP substrate kit for per-
oxidase (Vector Laboratories, Inc. Burlingame, CA, USA) were used,
following the manufacturer’s instructions. Quantification was performed
with MetaMorph software. Results were expressed as percentages of
stained area on total heart surface area.
Western blotting
Mousehearts were isolated after 30 min of ischaemia followedbyeither 5
or 15 min of reperfusion and were homogenized in lysis buffer containing
50 mM Tris, pH 7.5, 1 mM EDTA, pH 8.0, 150 mM NaCl, 1 mM PMSF, and
1 mM DTT. Total protein extracts were cleared by centrifugation and
40 mg of proteins separated by gel electrophoresis on 10% SDS–poly-
acrylamide gel followed by semi-dry transfer onto PVDF membranes.
Membranes were incubated with primary anti-phospho-Akt(Thr308),
anti-phospho-Akt(Ser473), anti-Akt, anti-phospho-p42/p44 MAPK,
anti-p42/p44 MAPK, anti-phospho-p38 MAPK, anti-p38 MAPK, anti-
phospho-Stat3(Ser727), anti-phospho-Stat3(Tyr705), anti-Stat3, anti-
phospho-SAPK/JNK(Thr183/Tyr185), and anti-SAPK/JNK antibody (all
A. Akhmedov et al.518
from Cell Signaling, Danvers, MA, USA). Primary anti-GAPDH (Millipore
Corporation, Billerica, MA, USA) antibodies were used as loading
control. Protein expression was quantified using Scion ImageTM and
expressed as ratio to corresponding loading control.
Mitochondrial swelling assay
Mitochondria (40 mg) from mouse hearts submitted to 30 min ischaemia
and 24 h of reperfusion were isolated in swellingbuffer (250 mM sucrose,
10 mM 3-(n-morpholino)propanesulfonic acid, 5 mM EGTA, 2 mM
MgCl2, 5 mM KH2PO4, 5 mM pyruvate, and 5 mM malate) were
incubated with 150 mM CaCl2 in a final volume of 200 mL in 96-well
plate for 20 min. Absorbance at 520 nm was read every 5 min.25
Caspase 3 assay
The caspase 3 assay was performed in total protein extracts from
murine hearts after 30 min ischaemia and 5–15 min of reperfusion,
using caspase 3 colorimetric assay kit (Sigma), according to manufac-
turer’s recommendations.
Apoptotic cell measurement within infarcted
hearts
Apoptosis was evaluated on cryosections of infarcted hearts after 30 min
of ischaemia and 24 h of reperfusion. The staining was performed using
the Dead EndTM colorimetric terminal deoxinucleotidyltransferase-
mediated dUTP nick end labelling (TUNEL) system (Promega, Madison,
WI, USA). Diaminobenzidine was used as the chromogenic substrate
(according to the manufacturer’s instructions). Results were expressed
as percentages of stained area on total heart surface area.
Statistical analysis
The Mann–Whitney nonparametric test (the normality assumption of
the variables’ distribution in both groups was violated) was used for com-
parisons of continuous variables. Kruskal–Wallis one-way analysis of
variance was used for multiple group comparison. All results are
expressed as mean+ SEM. Values of P, 0.05 (two tailed) were consid-
ered significant. All analyses were done with GraphPad Prism software
version 5.01.
Results
Expression pattern of p66Shc in cardiac
tissue
To determine the expression of p66Shc within cardiac tissue, we per-
formed in situ hybridization of paraffin-embedded cross sections of
perfused hearts isolated from WT and p66Shc2/2 mice using a
p66Shc-specific probe. In order to allocate p66Shc staining to cardio-
myocytes, we performed H/E staining of adjacent sections (Figure 1).
To visualize heart vessels and arterioles, we used smooth muscle
Figure 1 P66Shc expression pattern in mouse hearts. In situ hybridization with p66Shc mRNA LNA detection probe shows homogeneous expres-
sion of p66Shc in paraffin-embedded cross sections from wild-type (upper row) and p66Shc2/2 hearts (lower row). Consecutive heart cross sections
were stained with either p66Shc probe (left panels) or H/E (right panels).
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actin and CD31 immunostaining26 of cardiac and brain tissues. Com-
pared with WT no changes in either heart vessels (CD31+) or intra-
myocardial and coronary arterioles (SMA+) were noted in p66Shc2/2
mice (see Supplementary material online, Figures S1 and S2).
Infarct size after ischaemia and reperfusion
in wild-type and p66Shc2/2 mice
To investigate the impact of genetic deletion of p66Shc on infarct size,
we submitted mice to 30, 45, or 60 min of ischaemia followed by 24 h
Figure2 Genetic deletion of p66Shc promotes infarct size after short-term ischaemia in vivo. (A and B) Thirty minute of ischaemia followed by 24 h of
reperfusion.n ¼ 11 forWTandn ¼ 14 forp66Shc2/2. (A)Quantificationof areaat riskper ventricle area (P ¼ 0.3127). (B).Quantificationof infarct size
per ventricle area. Right panel: Representative images of 2-3-5-triphenyl tetrazolium chloride-stained middle heart sections of control wild-type and
p66Shc2/2mice. (C andD) Forty-five minutes of ischaemia followed by 24 h of reperfusion. n ¼ 14 for WT and n ¼ 9 for p66Shc2/2. (C) Quantification
of area at risk per ventricle area (P ¼ 0.8014). (D) Quantification of infarct size per ventricle area (P ¼ 0.6279). Right panel: Representative images of
2-3-5-triphenyl tetrazoliumchloride-stained-stainedmiddleheart sections ofwild typeandp66Shc2/2. (E and F) 60 min of ischaemia followedby24 h of
reperfusion.n ¼ 12 for wild typeandn ¼ 11 forp66Shc2/2. (E) Quantificationof areaat risk per ventricle area (P ¼ 0.4063). (F)Quantificationof infarct
sizeper ventricle area (P ¼ 0.6838).Rightpanel: Representative images of 2-3-5-triphenyl tetrazoliumchloride-stained-stainedmiddleheart sectionsof
wild type and p66Shc2/2. Serum cardiac troponin I levels of wild type or p66Shc2/2 after 30 (G), 45 (H ), or 60 (I) min of ischaemia followed by 24 h of
reperfusion. n ¼ 10 for both genotypes (P ¼ 0.0659 for H and P ¼ 0.8915 for I). Data are mean+SEM; *P, 0.05 vs. wild type.
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of reperfusion. The AAR after 30 min of ischaemia were comparable
for both genotypes indicating that coronary ligatures were placed at
the same level of the LAD in both groups (Figure 2A), p66Shc2/2mice
exhibited only increased infarct size after 30 min of ischaemia fol-
lowed by 24 h of reperfusion as compared with WT (I/V, mean+
SEM: 5.3%+2.7 vs. 2.4%+1.0, Figure 2B). In contrast, after pro-
longed ischaemia of 45 or 60 min, despite comparable areas at risk
(Figure 2C and E), infarct size was similar in both groups (Figure 2D
and F ). This indicates that p66Shc2/2 mice display an increased sus-
ceptibility to ischaemia leading to larger infarcts at shorter, but not
prolonged periods of ischaemia.
SerumcTnI levels (abiomarkerof cardiacnecrosis)22,27 confirmedthe
histological results with significantly higher levels in p66Shc2/2 mice only
after 30 minof ischaemia (Figure2G– I).Heart vessels (CD31+) or intra-
myocardial and coronary arterioles (SMA+) did not differ in p66Shc2/2
mice after ischaemia and reperfusion compared with WT as assessed by
smooth muscle actin and CD31 immunostaining, respectively (see Sup-
plementary material online, Figure S3).
Finally, we found that expression of p66Shc protein in the heart from
WT subjected to 30 min of ischaemia followed by either 12 or 24 h of
reperfusion was increased compared with p66Shc protein expression
without cardiac injury (see Supplementary material online, Figure S4).
Infarct size after ischaemia and reperfusion
during in vivo silencing of p66Shc
In order to investigate whether transient silencing of p66Shc has similar
effects on infarct size as in p66Shc2/2mice, we performed in vivo knock-
down of p66Shc in WT by injecting small interference RNA specific for
p66Shc or scrambled siRNA control into the tail vein. Four days after
siRNA application, mice were submitted to 30 min of ischaemia fol-
lowed by 24 h of reperfusion (Figure 3A). We first confirmed that
p66Shc was significantly downregulated at the protein level upon
in vivo siRNA treatment (Figure 3B) and that the AAR was similar
in all treatment groups (Figure 3C). Similar to p66Shc2/2 mice,
p66Shc-siRNA-mediated silencing was associated with a significant
increase in infarct size as compared with controls at 30 min of
ischaemia (14.9%+2.4 vs. 9.4%+2.9, Figure 3D and E). Again, there
was no difference in arteriole or vessel density in WT mice injected
Figure 3 In vivo knockdown of p66Shc in wild-type mice increases infarct size after short-term ischaemia. (A) Scheme of the experiment set up.
Scrambled (scr siRNA) or p66Shc siRNA was injected i.v. 4 days before in vivo ischaemia–reperfusion onset. Thirty minutes of ischaemia followed
by 24 h of reperfusion were applied. (B) Cardiac silencing of p66Shc by siRNA was analysed by western blot. Representative immunoblots from
four wild type injected with either scr siRNA or p66Shc siRNA. GAPDH immunoblot was used as a loading control. Bar graphs (left panels) represent
densitometric quantification of immunoblots of p66Shc protein. Data are mean+ SEM; n ¼ 8 for scr and n ¼ 11 for p66Shc siRNA; *P, 0.05 vs. scr
siRNA. (C) Quantification of area at risk per ventricle area (P ¼ 0.2884). (D) Quantification of infarct size per ventricle area. (E) Representative
images of 2-3-5-triphenyl tetrazolium chloride-stained middle heart sections of wild type injected either with scr siRNA or p66Shc siRNA.
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with p66Shc siRNA after ischaemia and reperfusion compared with
scramble injected WT (see Supplementary material online, Figure S5).
Genetic deletion or in vivo knockdown
of p66Shc do not influence inflammatory
processes during ischaemia and
reperfusion
In order to investigate whether genetic deletion or silencing of
p66Shc influences post-infarction inflammation (a critical mechan-
ism of injury during reperfusion)22,28 after short-term myocardial
ischaemia, we investigated systemic levels of CC and CXC chemo-
kines (attracting inflammatory cells),22 cardiac leukocyte infiltration
as well as cardiac oxidant content. No differences between
p66Shc2/2 and WT were noted in serum CXCL1 or CCL2 levels
at 30 (Table 1) min of ischaemia followed by 24 h of reperfusion.
Although some trend towards an increase for CXCL1 was observed
in WT mice submitted to in vivo siRNA-mediated knockdown
of p66Shc, serum levels of both CXCL1 and CCL2 remained
unchanged in p66Shc siRNA-treated animals when compared with
scr siRNA controls after 30 min of ischaemia and 24 h of reperfusion
(Table 1). As a consequence of these negligible differences between
genotypes on post-infarction circulating levels of CC and CXC che-
mokines, p66Shc2/2 mice and WT mice exhibited similar levels of
infiltrating neutrophils (Ly-6G+ cells, Supplementary material
online, Figure S6A), macrophages (see Supplementary material
online, Figure S6B), and ROS (assessed by 4-hydroxy-2-nonenal
[4-HNE], dibromotyrosine [DiBrY], superoxide [DHE] stainings,
respectively) (see Supplementary material online, Figure 6C–E).
Accordingly, in vivo p66Shc knockdown did not modify neutrophils
(Ly-6G+ cells, Supplementary material online, Figure S7A), macro-
phages (see Supplementary material online, Figure S7B), or ROS (see
Supplementary material online, Figure 7C–E) within infarcted hearts
when compared with scr siRNA controls. Finally, no significant
changes were observed in basal cardiac and brain ROS levels in
both groups of mice as assessed by 4-HNE and DiBrY stainings
(see Supplementary material online, Figures S8 and S9).
Genetic deletion of p66Shc prevents
activation of RISK and SAFE salvage
pathways
Activation of survival protective pathways in response to short-
term ischaemia early during reperfusion was then investigated.12,29
We examined phosphorylation levels of Akt, ERK1/2 and Stat3,
key members of RISK (Akt and ERK1/2) and SAFE (Stat3) intrinsic
prosurvival signalling pathways known to limit reperfusion injury,
during first 5 and 15 min of reperfusion. Significant abrogation in
the phosphorylation of Akt (Thr308) and Stat3 (Ser727) was
obvious at 5, but not at 15 min of reperfusion in p66Shc2/2 mice
when compared with WT, indicating a transient inhibition of
these salvage pathways (Figure 4A and C ). p66Shc deficiency was
not associated with any modification in the phosphorylation of
other amino acid residues of Akt (Ser473) or Stat3 (Tyr705)
neither at 5 nor at 15 min of reperfusion (Figure 4B and D). On
the other hand, no significant change in ERK1/2 phosphorylation
was noted in p66Shc2/2 animals when compared with WT (Supple-
mentary material online, Figure S10). Finally, both WT and p66Shc2/2
mice were treated with a single i.p. injection of the Stat3 inhibitor
WP1066 (40 mg/kg) or vehicle 5 min before ischaemia (30 min)
and 24 h of reperfusion (Figure 4E). Histological evaluation revealed
an AAR of 50–55% in all treatment groups (Figure 4F). The
infarct size was significantly increased in both WT and p66Shc2/2
WP1066-treated groups when compared with corresponding
vehicle controls (Figure 4G).
Genetic deletion and in vivo knockdown
of p66Shc promotes mitochondrial
swelling and apoptosis in infarcted
hearts
Phosphorylation of Stat3 on tyrosine 705 is known to drive p66Shc to
the nucleus, whereas the phosphorylation on serine 727 drives the
adaptor protein to the mitochondria where it regulates permeability
transition pores (PTP).30 To investigate the impact of Stat3 (Ser727)
phosphorylation on mitochondrial function, we performed swelling
assay using isolated mitochondria from WT and p66Shc2/2 infarcted
hearts induced by calcium chloride overload (CaCl2). The rate of
mitochondrial swelling was measured by light scattering at 520 nm.
Stable absorbance at 520 nm was observed up to 20 min in extracts
from WT mice. In contrast, mitochondria of p66Shc2/2 hearts dis-
played significantly increased absorbance 15 and 20 min after
CaCl2 overload reflecting markedly increased swelling and thus mito-
chondrial disruption (Figure 5A). Accordingly, caspase-3 activity was
increased in heart extracts from p662/2 mice after 15 min of reper-
fusion when compared with WT (Figure 5B).
We then assessed the effects of p66Shc deficiency on cardiac apop-
tosis after 30 min of ischaemia and 24 h reperfusion. In line with the
activation of caspase-3, p66Shc deficiency was associated with an
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Table 1 Serum levels of CXCL1 (neutrophil chemoattractant) and CCL2 (monocyte/macrophage chemoattractant)
after 30 min of ischaemia and 24 h reperfusion
Chemoattractant (pg/mL) Genetic deletion Transient knockdown
WT p66Shc2/2 scr siRNA p66 siRNA
CXCL1 579.3+635.7 476.6+590.0 361.8+234.6 515.2+275.6
CCL2 28.2+18.69 31.1+17.35 54.7+26.7 56.4+32.34
Data are presented as mean+ SD; n ¼ 10–18 per group.
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Figure 4 Genetic deletion of p66Shc inhibits early activation of salvage signalling pathways in infarcted hearts. After 30 min ischaemia followed by
5–15 min of reperfusion, hearts were lysed and phosphorylation of intracellular kinases assessed by western blot. n ¼ 7 for wild type and n ¼ 6 for
p66Shc2/2. Data are mean+ SEM. *P, 0.05 vs. wild type. (A) Akt (Thr308) phosphorylation (P ¼ 0.8982 for 15 min). (B) Akt (Ser473) phosphor-
ylation (P ¼ 0.8610 for 5 min andP ¼ 0.1544 for 15 min). (C) Stat3 (Ser727)phosphorylation (P ¼ 0.1443 for 15 min). (D) Stat3 (Tyr705)phosphor-
ylation (P ¼ 0.2153 for 5 min and P ¼ 0.9163 for 15 min). (E) Scheme of the experiment set up. WP1066 or vehicle was injected i.v. 5 min before
in vivoonset of 30 min ischaemia in wild type and p66Shc2/2. At 24 h of reperfusion mice were euthanized and infarct size assessed. (F) Quantification
of area at risk per ventricle area (P ¼ 0.1429 forwild type andP ¼ 0.0971 forp66Shc2/2). (G) Quantificationof infarct size per ventricle area. (C)Right
panel: Representative images of 2-3-5-triphenyl tetrazolium chloride-stained middle heart sections of wild type and p66Shc2/2.
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increased Tunel-positive cell content when compared with WT
(Figure 5C). A similar result was also seen in p66Shc siRNA-treated
mice when compared with scr siRNA controls (Figure 5D).
Discussion
This study for the first time demonstrates that, unlike in the brain,19
p66Shc protects the myocardium during short-term ischaemia and
reperfusion from injury in vivo in mice. Indeed, we showed that
(1) p66Shc is expressed both in the myocardium and the coronary
vasculature, (2) p66Shc2/2 mice display increased infarct size when
compared with WT controls when exposed to a short-term
period of ischaemia only (i.e. 30 min), (3) similar effects can be
obtained in WT mice by transient silencing of p66Shc using siRNA,
(4)p66Shc regulates salvagepathways, and (4)preventsmitochondrial
swelling and apoptosis via caspase-3.
P66Shc is differentially expressed in different organs and tissues.
Importantly, unlike in the brain (where p66Shc is exclusively expressed
in the endothelium of blood vessels),19 in the heart the adaptor
protein is expressed both in myocardial tissue and coronary blood
Figure 5 Genetic deletion of p66Shc is associated with postinfarction mitochondrial dysfunction and increased apoptosis in infarcted hearts.
(A) Light absorbance at 520 nm in wild type and p66Shc2/2 infarcted hearts (30 min ischaemia and 24 h reperfusion) at 15 and 20 min of calcium
overload (150 mM of CaCl2). Values are shown as percentage of average absorbance of wild type extracts in the absence of calcium (n ¼ 4/
group). (B) Caspase-3 activity in infarcted heart extracts in wild type and p66Shc2/2, submitted to 30 min ischaemia and 5 and 15 min of reperfusion
(n ¼ 4/group, P ¼ 0.2222 for 5 min). (C) Quantification of Tunel-positive areas in frozen sections of infarcted hearts from wild type or p66Shc2/2
submitted to30 min of ischaemia followedby24 hof reperfusion (n ¼ 8 forwild typeandn ¼ 6 forp66Shc2/2). Right panel: Representative imagesof
Tunel staining are shown. (D) Quantification of Tunel-positive areas in frozen sections of infarcted hearts from wild type treated with scrambled
(scr siRNA) or p66Shc siRNA and submitted at 30 min of ischaemia followed by 24 h of reperfusion (n ¼ 7 for scr and n ¼ 6 for p66Shc siRNA).
Right panel: Representative images of Tunel stainings are shown. Data are mean+ SEM. *P, 0.05 vs. wild type.
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vessels. At baseline, p66Shc knockout mice did not differ from WT in
their vessel structure and density or metabolism of reactive oxidant
species in both the heart and brain. Similarly, in infarcted hearts
after 30 min of ischaemia and 24 h of reperfusion, no histological
alterations of vessel density and structure or oxidant content were
notable. This demonstrates that p66Shc plays distinct roles at baseline
and in response to an ischaemic insult in the heart and brain.
The surprising fact that both genetic deletion or transient silencing
of p66Shc led to increased infarct size after 30, but not after 45 and
60 min of ischaemia followed by 24 h reperfusion was supported by
histological and biochemical data using troponin I as a marker. These
solid observations are in contrast to previous ex vivo studies using iso-
lated perfused hearts where p66Shc deletion appeared toprevent from
ischaemia–reperfusion injury.20 Thus, as in other experimental situa-
tions, it is obvious that results obtained in isolated organs and tissues
mostly perfused by artificial solutions and devoid of physiological
filling pressure and neurohumoural regulation cannot be extrapolated
to the in vivo situation. Indeed, ex vivo and in vivo models of ischaemic
cardiac injury differ substantially (including different times of reperfu-
sion and involvement of systemic inflammation).22,28
As in thebrainwherep66Shc is onlyexpressed in thevasculature, but
not in neurons and in hepatic ischaemic injury p66Shc contributes to
reperfusion injury, we here demonstrate a differential role of p66Shc
in the myocardium. Indeed, in endothelial cells, p66Shc inhibits the
expression and activity of eNOS and increases O2
− production.31–34
However, the microcirculation of the heart (which is of importance
during ischaemia) is mainly regulated by endothelium-derived hyper-
polarizing factors rather than eNOS.17,35,36 Thus, the protective
effects of p66Shc against short-term ischaemia and reperfusion
must be related to a specific role of the adaptor protein in the myo-
cardium. Indeed, in the heart, ROS may also play a protective role in
response to ischaemia.22,37 However, underour experimental condi-
tions, p66Shc silencing unlike in the murine aorta did not alter ROS
production confirming a different regulatory role of p66Shc in the
heart compared with other organs.38 Thus, the protective role of
p66Shc in the myocardium must involve other pathways than those
described in endothelial cells of conduit arteries. Indeed, the fact
that protein levels of p66Shc in the infarcted hearts from WT mice
increase after 30 min of ischaemia followed by 12 or 24 h of reperfu-
sion support our initial hypothesis of a protective role of p66Shc in the
myocardium.
Further, p66Shc deficiency was not associated with any modifica-
tion in both systemic and cardiac inflammation postinfarction.
This again was surprising, since inflammation is considered a critical
mediator of myocardial injury after ischaemia and reperfusion.5,6
However, our findings are in accordance with recent studies in
animal models of acute myocardial infarction, in which the relevance
of pro-inflammatory mediators (such as cytokines and chemokines)
was questioned.39 Furthermore, no anti-inflammatory interventions
have been shown to be clinically effective.40–42 It even has been sug-
gested that inhibition of certain chemokines may favour scar forma-
tion, salvage of post-infarction remodelling and mouse survival.27 On
the other hand, others found that inhibiting CXC chemokines early
after ischaemia may reduce infarct size, but ineffective in preventing
post-infarction heart failure.43,44 Be it as it may, p66Shc does clearly
not exert its protective effects via modulation of inflammatory
responses or ROS activated during ischaemia and reperfusion.
Importantly, we found that p66Shc is a critical regulator of cardiac
protective pathways in mice. Indeed, p66Shc deficiency was asso-
ciated with a reduction in the phosphorylation levels of Akt at the
Thr308 site and Stat3 at the Ser727 site after 5 min of reperfusion.
Moreover, pharmacological inhibition of Stat3 activation through
phosphorylation shortly before ischaemia onset further confirmed
that Stat3 mediates the protective effects of p66Shc during ischaemia–
reperfusion. In line with that, activation of certain intracellular
kinases, in particular those that are part of the RISK and SAFE path-
ways (i.e. Akt and Stat3), has been proposed as a preventive strategy
against reperfusion injury.12,45 Interestingly, to be protective against
ischaemia, Akt must not be fully activated (i.e. phosphorylated at
both Thr308 and Ser473).46 This may explain why p66Shc, although
it selectively phosphorylates Akt only at the Thr308 residue, was
able to activate the RISK pathway in the ischaemic myocardium.
p66Shc-mediated phosphorylation of Stat3 at Ser727 is of importance
for mitochondrial respiration of cardiomyocytes during ischaemia as
phosphorylation of Stat3 at Ser727 promotes the transcriptional
activity and mitochondrial translocation of this kinase.47 Data in
mice and pigs confirmed the importance of Stat3 phosphorylation
at Ser727 and Tyr705, respectively, for its mitochondrial localization
and its effect on mitochondrial respiratory complex 1 and 2 as well as
on mPTP.48,49 Our data are in accordance with those data further
extending the role of Ser727 phosphorylation on mitochondrial
permeability transition process by regulating mitochondrial PTP
status. Finally, considering that other potential intracellular pathways
were only marginally affected by p66Shc deficiency, p66Shc appears to
act selectively on these intracellular pathways during ischaemia and
reperfusion.
In line with these findings, we further show for the first time that
genetic deletion or transient silencing of p66Shc is associated with
increased apoptosis post-infarction in response to short-term
ischaemia and reperfusion. In line with these morphological findings,
caspase-3 activity was increased and marked mitochondrial swelling
was noted in infarcted hearts obtained from p66Shc2/2 when com-
pared with WT animals. Of note, post-infarction cardiac apoptosis
is a key event in adverse cardiac remodelling and heart failure
during follow-up.50
Study limitations
First, extrapolations from mouse models to the human situation are
difficult. Thus, although p66Shc is upregulated in peripheral cells of
patients with infarction further experiments in human myocardial
tissue should be considered. Second, we acknowledge that infarct
size observed in the present study was rather small compared with
the infarct size found in humans, and accordingly small was the poten-
tial forprotection. Third, the useof conventional knockout micedoes
not exclude effects of p66Shc deletion in the other cell types than car-
diomyocytes. Fourth, it is not clear yet whether further activation of
p66Shc over the basal level would be beneficial. To sort this out, the
development of mice overexpressing p66Shc in the myocardium
would be essential. Fifth, although we were able to identify p66Shc
as a regulator of protective pro-survival RISK and SAFE pathways
within ischaemic hearts, we did not identify all intermediate mole-
cules involved. Finally, the present study also adds complexity to
the use of this salvage pathways as a potential therapeutic target.
Indeed, given the different effects of activation and silencing of
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p66Shc in different cells, tissues, and organs,17 tissue selective
inhibition was shown to be effective in mice. Indeed, while short-
term activation might be protective in the context of an acute myo-
cardial infarction, long-term inhibition may prevent endothelial dys-
function,34,38 atherosclerosis, and diabetic vascular disease in
mouse models.21,34 Obviously, this complexity also raises safety
and bio-efficacy concerns for translating these results to human
domain. Additional research is needed to further clarify the role of
p66Shc in other animal models of acute myocardial infarction,
before speculating on human diseases.
Supplementary material
Supplementary material is available at European Heart Journal online.
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